Abstract Details

Title Prevalent Gabapentinoid Use Among Medicare Beneficiaries with Acute Ischemic Stroke

Topic Cerebrovascular Disease and Interventional Neurology

Presentation(s) P8 - Poster Session 8 (11:45 AM-12:45 PM)

Poster/Presentation
Number 5-022

Objective To estimate the prevalence and correlates of gabapentinoid prescriptions among older adults presenting with acute ischemic stroke (AIS).

Background Little is known about patterns of gabapentinoid use among older adults hospitalized for stroke, who are more vulnerable to side effects.

Design/Methods We conducted a retrospective analysis of 2009-2022 claims data from a 20% sample of U.S. Medicare beneficiaries aged 65 years and older hospitalized for AIS. We included patients without prior stroke enrolled in traditional Medicare Parts A, B, D coverage for 12 or more months before hospitalization. We analyzed gabapentinoid prescription claims 6 months prior to AIS hospitalization, estimating prevalent users by year, U.S. census division, and age group.

Results Among 271,011 beneficiaries hospitalized for AIS between 2009 and 2022, 32,237 (11.9% [95% CI: 11.8 – 12.0]) had gabapentinoid prescription claims prior to hospitalization. Median age was 79 (Quartile Range: 73 – 86), 60% were women, and 80% were Non-Hispanic White. Prevalent gabapentinoid users increased from 8.5% [95% CI: 8.2 – 8.9] in 2009 to 13.7% [95% CI: 13.0 – 14.5] in 2022. The largest prevalence rate difference between U.S. Census divisions was observed for the Mid-Atlantic (9.4% [95% CI: 9.1 – 9.7]) division vs. the East South-Central division (14.9% [95% CI: 14.5 – 15.4]). Prevalent gabapentinoid use decreased with advancing age group, with 15.6% [95% CI: 15.2 – 15.9] prevalent use among 65-69 year-olds and 9.6% [95% CI: 9.4 – 9.8] among 85+ year-olds.

Conclusions Many Medicare beneficiaries hospitalized for AIS were using gabapentinoids preadmission. The prevalence rate increased between 2009 and 2022 and varied significantly by geographic region.

Authors/Disclosures
Julianne Brooks PRESENTER	Julianne Brooks has nothing to disclose.
Rebeka Bustamante Rocha, Other	Mrs. Bustamante Rocha has nothing to disclose.
Maria Donahue (Massachusetts General Hospital)	Maria Donahue has nothing to disclose.
Madhav Sankaranarayanan	Mr. Sankaranarayanan has nothing to disclose.
Christine Ritchie (Massachusetts General Hospital)	No disclosure on file
Sebastien Haneuse (Harvard T.H. Chan School of Public Health)	Sebastien Haneuse has received personal compensation for serving as an employee of Harvard University. Sebastien Haneuse has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for American Medical Association.
I-Ching Tsai, MHA	Mrs. Tsai has received personal compensation for serving as an employee of Johnson&Johnson. Mrs. Tsai has stock in Johnson & Johnson.
Lidia Maria V. Moura, MD, PhD, MPH, FAAN (Massachusetts General Hospital)	Dr. Moura has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for UCB. Dr. Moura has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Pfizer. The institution of Dr. Moura has received research support from Centers for Diseases Control and Prevention (CDC SIP20-007) . The institution of Dr. Moura has received research support from Epilepsy Foundation of America . The institution of Dr. Moura has received research support from NIH - NIA and NINDS. Dr. Moura has received personal compensation in the range of $50,000-$99,999 for serving as a Expert Advisor with Epilepsy Foundation .

��ɫ��

��ɫ��